Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14522328 | 1.00 | CHRM5 (0.35) | CHRM5CHRM3HSD17B10SIGMAR1TSHR | |
| SCHEMBL12231841 | 0.99 | CHRM5 (0.34) | CHRM5CHRM3HSD17B10SIGMAR1TSHR | |
| SCHEMBL1241407 | 0.93 | CHRM5 (0.39) | CHRM5CHRM3SIGMAR1EGFR | |
| SCHEMBL29673006 | 0.91 | CHRM5 (0.38) | CHRM5CHRM3SIGMAR1EGFR | |
| SCHEMBL560792 | 0.91 | HSD17B10 (0.39) | HSD17B10TSHRSLC6A9 | |
| SCHEMBL15518427 | 0.91 | HSD17B10 (0.39) | HSD17B10TSHRSLC6A9 | |
| SCHEMBL6666931 | 0.89 | SLC6A9 (0.33) | CHRM5CHRM3SLC6A9 | |
| SCHEMBL17057486 | 0.87 | HSD17B10 (0.36) | CHRM5CHRM3HSD17B10TSHRSLC6A9 | |
| SCHEMBL17053358 | 0.87 | HSD17B10 (0.36) | CHRM5CHRM3HSD17B10TSHRSLC6A9 | |
| SCHEMBL25518167 | 0.84 | HSD17B10 (0.32) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | CHRM5 4806/4885CHRM3 4745/4885HSD17B10 1777/4885 |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | CHRM5 4806/4885CHRM3 4745/4885HSD17B10 1777/4885 |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | FIBP, FGFR2, FGFR1 | CHRM5 4790/4885CHRM3 4788/4885HSD17B10 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.